Immunohistochemical analysis of the monoclonal antibody 4B5 in breast tissue expressing human epidermal growth factor receptor 4 (HER4)

Jay, Julie I; Brunhoeber, Patrick; Smith, Margie H; Williams, Ryan; Sugarman, Michael C.; Free, Heather L; Tast, David E

doi:10.1111/his.12024

Cited by 4 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently a large number of HER4 antibodies were screened using both cell lines transfected with HER1, HER2, HER3, and HER4; and breast carcinoma samples [29]. The anti-HER4 clone E200 showed the greatest sensitivity and specificity for HER4 detection.…”

Section: Introductionmentioning

confidence: 99%

HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma

et al. 2013

View full text Add to dashboard Cite

Prognostic and predictive markers utilized in invasive breast carcinoma are limited and include ER, PR, Ki67, and ERBB2 (HER2). In the case of HER2, over-expression or amplification serves as eligibility for anti-HER2 based therapy, including trastuzumab (Herceptin®, Genentech). While clinical trials have shown trastuzumab improves overall survival and time to progression, an individual's response to anti-HER2 based therapy is highly variable. This suggests that, in a “uniform” HER2 positive population, additional markers could help in predicting patient outcome to therapy. Here we utilized a recently validated high-specificity HER4 antibody (E200) and generated a standard clinical HER4 scoring algorithm (HER4 H-Score) utilizing two breast carcinoma cohorts: 1) patients receiving neoadjuvant trastuzumab (n=47) and 2) patients receiving trastuzumab for metastatic disease (n=33). Our HER4 H-Score showed significant correlation with high sensitivity RT-qPCR performed on matched patients (p=<0.0001). In addition, patients with HER2/HER4 co-over-expression status showed a significant delay in development of metastasis after neo-adjuvant trastuzumab therapy (p= 0.04) and showed a significant improvement in progression free survival after adjuvant trastuzumab therapy (p=0.03). These findings suggest HER4 IHC, used in conjunction with a standard HER2 testing algorithm, could aid in predicting clinical outcome and help identify patients likely to show improved response to trastuzumab therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma

et al. 2013

View full text Add to dashboard Cite

show abstract

Development of a highly specific HER2 monoclonal antibody for immunohistochemistry using protein microarray chips

Zhou

et al. 2017

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

Distinguishing Score 0 From Score 1+ in HER2 Immunohistochemistry-Negative Breast Cancer

Lambein

Bockstal

Vandemaele

et al. 2013

American Journal of Clinical Pathology

View full text Add to dashboard Cite

show abstract

Immunohistochemical analysis of the monoclonal antibody 4B5 in breast tissue expressing human epidermal growth factor receptor 4 (HER4)

Abstract: No cross-reactivity of 4B5 with membrane-bound HER4 was identified in the clinical IHC analysis of formalin-fixed paraffin-embedded breast carcinoma cases as evidenced by the HER4 antibody clone E200.

Cited by 4 publications

References 29 publications

HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma

HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma

Development of a highly specific HER2 monoclonal antibody for immunohistochemistry using protein microarray chips

Distinguishing Score 0 From Score 1+ in HER2 Immunohistochemistry-Negative Breast Cancer

Contact Info

Product

Resources

About